|
CNS disorders: what the future holds for drugs and therapies
|
NeuroDrug 2007 focuses on drug discovery and development across the CNS sector. NeuroDrug will cover key neurological disorders such as epilepsy and chronic pain, neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease and psychiatric conditions such as depression, schizophrenia and anxiety disorders.
The huge gaps in drug development for CNS disorders are best addressed through scientific and industrial partnerships. NeuroDrug 2007 is the leading event to meet with industry peers, learn about new targets and advance your understanding of latest techniques and business strategies. This is an event not to be missed. |
|
|
‘NeuroDrug is a forward thinking event that aids the participants to examine current hot topics as well as to look ahead to the future directions in neurological drug discovery. For this reason, key personnels in academia and industry alike can expect to gain exciting threads of scientific ideas that may lead to research that would ultimately benefit patients with neurological diseases.’
Dr Aaron Chuang, Drug Discovery Stem Cell Coordinator and Manager of Cellular Neurobiology, Neurodegeneration Research Department, GlaxoSmithKline
> Register your place today!
> Find out about sponsorship opportunities |
|
|
|
|
|
|
|
|
Dr Antony Altar,
Director of the Biomarkers Consortium,
Foundation for the NIH |
Dr Trevor Howe,
Head of Molecular Informatics,
Johnson & Johnson PRD |
Dr Aaron Chuang,
Manager of Cellular Neurobiology,
Glaxosmithkline |
Dr Bengt von Mentzer,
Principal Scientist, Molecular Pharmacology Discovery,
AstraZeneca |
Michael J O'Neill,
Research Advisor, Neurodegeneration Drug Team,
Eli Lilly |
Dr Klaus Mendla,
Head of CNS Therapeutic Advisory Team, Boehringer Ingelheim |
|
Extended networking at NeuroDrug 2007
 This is the revolutionary, exciting, quick and highly effective way to meet fellow conference delegates and industry peers in one 45 minute session. These brief meetings are the starting point for conversation and networking throughout the conference. This is where long-lasting and profitable business relationships begin. Make sure you bring plenty of business cards!
 We introduce you to ‘Contact’- a system to enable you to set up meetings before the event. You can search the attendees then email them directly without ever seeing their e-mail address. The first contact is made and you can take it from there. More than just networking; Important forms and conference tips can be downloaded and after the event you can even download the white papers and presentations from our world-class speakers.
 NeuroDrug 2007 offers you more CEO and Director level panel discussions. There will be several “chat show” style sessions where you can get answers to your questions. You will not get a better chance than this to question the leading players in the global CNS industry.
|
|
|
Capitalise on the future of the CNS industry
Q1: Do you target decision makers from the pharmaceutical and biotech industry?
Q2: Can you provide a solution to some of the challenges in CNS drug discovery and development?
Q3: Can you show our delegates how to advance their CNS drug development?
If so then NeuroDrug 2007 is the leading platform for you to meet your target market. NeuroDrug 2007 will cover the key commercial challenges in CNS drug development, which include new therapeutic targets, drug delivery and the blood brain barrier, regulation, clinical trials, reducing the cost of manufacturing and improving speed to market, patent and intellectual property, funding and investment and novel therapies such as gene therapy and stem cells.
|
|
Target your market!
Limited sponsorship opportunities exist for this event.
For full details contact
Ince Saleem or call +44 (0) 207 092 1323 | |
|
|
|
|
|
|
|
|
Dr Nicholas Moore,
Associate Director, Behavioural Pharmacology,
Lundbeck Research USA Inc. |
Dr Lee Schechter,
Therapeutic Area Head/Director, Depression and Anxiety Research, Neuroscience Discovery,
Wyeth Research |
Dr Henrik Klitgaard,
Vice President of CNS Research,
UCB Pharma SA
|
Dr Shaun Jordan,
Associate Director, Neuroscience Research,
Otsuka Maryland Medicinal Labs |
Dr Anders Haegerstrand,
Vice President and Chief Scientific Officer,
NeuroNova |
Dr John Sinden,
Founder and Chief Scientific Officer,
ReNeuron
| |
